A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1048312

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $1,169,549.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

blood diseases | blood disorders | clinical research | clinical trial | leukaemia | signal transduction | signalling pathways

Related Links